Drug intelligence / Profile preview

TPC-032

Development stage: Preclinical
Lead developer: Tetra Pharm Technologies
Modality: Small Molecules

Overview

TPC-032 is an investigational small molecule drug candidate being developed by Tetra Pharm Technologies for the treatment of rheumatoid arthritis. As part of Tetra Pharm's research and development pipeline, TPC-032 is designed to target the endocannabinoid system (ECS), which plays a significant role in regulating immune responses and inflammation. While the specific molecular structure and target (such as CB1 or CB2 receptors) remain proprietary, the drug aims to leverage the anti-inflammatory properties of cannabinoid-based compounds to provide a new therapeutic option for patients with chronic inflammatory joint diseases. It is currently in the discovery to pre-clinical stage of development.

Beyond the preview

Go deeper on TPC-032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPC-032.

Explore the full profile